Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Bristol-Myers Squibb
Exelixis
Neonc Technologies, Inc.
Myeloid Therapeutics
Mayo Clinic
University of California, Irvine